Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.

@article{Badesch2007SildenafilFP,
  title={Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.},
  author={David B. Badesch and Nicholas S Hill and Gary Burgess and Lewis J. Rubin and Robyn J. Barst and Nazzereno Gali{\`e} and G{\'e}rald Simonneau},
  journal={The Journal of rheumatology},
  year={2007},
  volume={34 12},
  pages={2417-22}
}
OBJECTIVE Pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD) is difficult to manage, and has a poor prognosis. The phosphodiesterase-5 inhibitor sildenafil citrate enhances vasodilatation, has antiproliferative effects, and is effective in the treatment of PAH. We examined the efficacy and safety of oral sildenafil in patients with PAH-CTD. METHODS In a 12-week, double-blind study (SUPER-1), 278 patients with PAH were randomized to oral placebo, sildenafil 20… CONTINUE READING